Christopher D Zahm
age ~45
from Madison, WI
- Also known as:
-
- Chris Dennis Zahm
- Chris D Last
- Phone and address:
- 4509 Rigney Ln, Madison, WI 53704
Christopher Zahm Phones & Addresses
- 4509 Rigney Ln, Madison, WI 53704
- Oconomowoc, WI
- 427 3Rd St, Washburn, WI 54891 • 7153732800 • 7156859965
- Ashland, WI
- Waukesha, WI
Work
-
Company:University of wisconsin-madisonSep 2014
-
Position:Scientist i
Education
-
Degree:Doctorates, Doctor of Philosophy
-
School / High School:University of Wisconsin - Madison2009 to 2014
Skills
Cancer Research • Epifluorescent Microscopy • Cell Biology • Elisa • Recombinant Dna • Small Animal Models • Mouse Genetics • Animal Husbandry • Confocal Microscopy • Pcr • Immunofluorescence • Small Animal Imaging • Dna • Immunology • Cell Culture • Fluorescence • Molecular Biology • Polymerase Chain Reaction • Oncology • Mouse Models of Intestinal Cancer • Immunohistochemistry • Recombinant Dna Technologies • Tumor Immunology • Cancer Cell Biology • Cancer • Epifluorescent • Research • Transgenic Mice • Flow Cytometry • Fluorescence Microscopy • Tissue Culture • Microscopy • Cancer Biology • 3D Microscopy
Languages
English
Interests
Cancer Immunology • Biological Imaging • Mouse Models of Cancer
Industries
Higher Education
Resumes
Scientist I
view sourceLocation:
Madison, WI
Industry:
Higher Education
Work:
University of Wisconsin-Madison
Scientist I
Medical College of Wisconsin Jun 2007 - Sep 2007
Summer Program For Undergraduate Research Participant
Scientist I
Medical College of Wisconsin Jun 2007 - Sep 2007
Summer Program For Undergraduate Research Participant
Education:
University of Wisconsin - Madison 2009 - 2014
Doctorates, Doctor of Philosophy University of Wisconsin - Madison 2007 - 2009
Bachelors, Bachelor of Science, Biochemistry Uw - Milwaukee at Waukesha 2005 - 2007
Associates, Associate of Arts, Biological Science
Doctorates, Doctor of Philosophy University of Wisconsin - Madison 2007 - 2009
Bachelors, Bachelor of Science, Biochemistry Uw - Milwaukee at Waukesha 2005 - 2007
Associates, Associate of Arts, Biological Science
Skills:
Cancer Research
Epifluorescent Microscopy
Cell Biology
Elisa
Recombinant Dna
Small Animal Models
Mouse Genetics
Animal Husbandry
Confocal Microscopy
Pcr
Immunofluorescence
Small Animal Imaging
Dna
Immunology
Cell Culture
Fluorescence
Molecular Biology
Polymerase Chain Reaction
Oncology
Mouse Models of Intestinal Cancer
Immunohistochemistry
Recombinant Dna Technologies
Tumor Immunology
Cancer Cell Biology
Cancer
Epifluorescent
Research
Transgenic Mice
Flow Cytometry
Fluorescence Microscopy
Tissue Culture
Microscopy
Cancer Biology
3D Microscopy
Epifluorescent Microscopy
Cell Biology
Elisa
Recombinant Dna
Small Animal Models
Mouse Genetics
Animal Husbandry
Confocal Microscopy
Pcr
Immunofluorescence
Small Animal Imaging
Dna
Immunology
Cell Culture
Fluorescence
Molecular Biology
Polymerase Chain Reaction
Oncology
Mouse Models of Intestinal Cancer
Immunohistochemistry
Recombinant Dna Technologies
Tumor Immunology
Cancer Cell Biology
Cancer
Epifluorescent
Research
Transgenic Mice
Flow Cytometry
Fluorescence Microscopy
Tissue Culture
Microscopy
Cancer Biology
3D Microscopy
Interests:
Cancer Immunology
Biological Imaging
Mouse Models of Cancer
Biological Imaging
Mouse Models of Cancer
Languages:
English
Us Patents
-
Ido Activity As A Marker Of Tumor Immune Escape And Ido Inhibitors As A Means Of Enhancing T Cells Response To Antigen Specific Vaccine
view source -
US Patent:20220218809, Jul 14, 2022
-
Filed:Nov 6, 2019
-
Appl. No.:17/291159
-
Inventors:- Madison WI, US
Christopher D. Zahm - Madison WI, US
Laura Johnson - Madison WI, US -
Assignee:Wisconsin Alumni Research Foundation - Madison WI
-
International Classification:A61K 39/00
A61P 35/00
A61K 39/395
A61K 31/4245 -
Abstract:The present invention provides compositions and methods of treating prostate cancer using a combination of a DNA vaccine, PD-1 inhibitor and an IDO inhibitor. Further, methods of measuring IDO activity as a way to identify a subpopulation of subjects with prostate cancer that may benefits from the treatment methods described herein are provided.
-
Tlr Agonists For Reducing Activation-Induced Pd-1 Expression On T Cells And Methods Of Use
view source -
US Patent:20180169224, Jun 21, 2018
-
Filed:Dec 12, 2017
-
Appl. No.:15/838824
-
Inventors:- Madison WI, US
Christopher D. Zahm - Madison WI, US -
International Classification:A61K 39/39
A61P 35/00
A61K 39/00 -
Abstract:The present invention is directed toward methods of increasing the immune response to an antigen using TLR1/2 agonist and/or TLR7 agonist in combination with a T cell activating treatment, for example, a vaccine. In some aspects, the present invention provides methods of enhancing an anti-tumor response comprising administering at least one TLR1/2 agonist and/or at least one TLR7 agonist in combination with an immunotherapeutic agent.
-
Pi3-Kinase Inhibition And Lag-3 Checkpoint Blockade As A Combination Therapy For Cancer
view source -
US Patent:20180043011, Feb 15, 2018
-
Filed:Aug 10, 2017
-
Appl. No.:15/674066
-
Inventors:- Madison WI, US
Viswa T. Colluru - Salt Lake City UT, US
Christopher D. Zahm - Madison WI, US -
International Classification:A61K 39/395
C07K 16/28
A61K 39/00
A61K 31/4745 -
Abstract:This disclosure provides methods of treating cancer comprising administering at least one PIK inhibitor and at least one LAG- checkpoint inhibitor. Suitable compositions are also disclosed.
Googleplus
Christopher Zahm
Youtube
Get Report for Christopher D Zahm from Madison, WI, age ~45